Your browser doesn't support javascript.
loading
External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy.
Norrish, Gabrielle; Qu, Chen; Field, Ella; Cervi, Elena; Khraiche, Diala; Klaassen, Sabine; Ojala, Tiina H; Sinagra, Gianfranco; Yamazawa, Hirokuni; Marrone, Chiara; Popoiu, Anca; Centeno, Fernando; Schouvey, Sylvie; Olivotto, Iacopo; Day, Sharlene M; Colan, Steve; Rossano, Joseph; Wittekind, Samuel G; Saberi, Sara; Russell, Mark; Helms, Adam; Ingles, Jodie; Semsarian, Christopher; Elliott, Perry M; Ho, Carolyn Y; Omar, Rumana Z; Kaski, Juan P.
Afiliação
  • Norrish G; Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London WC1N 3JH, UK.
  • Qu C; Institute of Cardiovascular Sciences, University College London, London, UK.
  • Field E; Department of Statistical Science, University College London, London, UK.
  • Cervi E; Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London WC1N 3JH, UK.
  • Khraiche D; Institute of Cardiovascular Sciences, University College London, London, UK.
  • Klaassen S; Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London WC1N 3JH, UK.
  • Ojala TH; Necker - Enfants Malades hospital, Paris, France.
  • Sinagra G; Department of Paediatric Cardiology, Charite - Universitatsmedizin Berlin, Berlin, Germany.
  • Yamazawa H; Experimental and Clinical Research Centre (ECRC), a joint cooperation between the Charité Medical Faculty and the Max-Delbrück-Centre for Molecular Medicine (MDC), Charite - Universitatsmedizin Berlin, Berlin, Germany.
  • Marrone C; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
  • Popoiu A; Department of Paediatric Cardiology, New Children's Hospital, University of Helsinki, Helsinki, Finland.
  • Centeno F; Heart Muscle Disease Registry Trieste, University of Trieste, Trieste, Italy.
  • Schouvey S; Department of Paediatrics, Faculty of Medicine and Graduate school of Medicine, Hokkaido University Hospital, Sapporo, Japan.
  • Olivotto I; Fondazione Toscana G Monasterio, Massa-Pisa, Italy.
  • Day SM; Department of Paediatrics, Children's Hospital 'Louis Turcanu', University of Medicine and Pharmacy "Victor Babes" Timisoara, Timisoara, Romania.
  • Colan S; Rio Hortega University Hospital, Valladolid, Spain.
  • Rossano J; Hospital Saint Joseph, Marseille, France.
  • Wittekind SG; Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy.
  • Saberi S; Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Russell M; Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Helms A; Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Ingles J; Cincinnati Children's Hospital Medical Center, Heart Institute, Cincinnati, OH, USA.
  • Semsarian C; Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor, MI, USA.
  • Elliott PM; Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor, MI, USA.
  • Ho CY; Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor, MI, USA.
  • Omar RZ; Cardio Genomics Program at Centenary Institute, The University of Sydney, Sydney, Australia.
  • Kaski JP; Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, The University of Sydney, Sydney, Australia.
Eur J Prev Cardiol ; 29(4): 678-686, 2022 03 30.
Article em En | MEDLINE | ID: mdl-34718528
ABSTRACT

AIMS:

Sudden cardiac death (SCD) is the most common mode of death in childhood hypertrophic cardiomyopathy (HCM). The newly developed HCM Risk-Kids model provides clinicians with individualized estimates of risk. The aim of this study was to externally validate the model in a large independent, multi-centre patient cohort. METHODS AND

RESULTS:

A retrospective, longitudinal cohort of 421 patients diagnosed with HCM aged 1-16 years independent of the HCM Risk-Kids development and internal validation cohort was studied. Data on HCM Risk-Kids predictor variables (unexplained syncope, non-sustained ventricular tachycardia, maximal left ventricular wall thickness, left atrial diameter, and left ventricular outflow tract gradient) were collected from the time of baseline clinical evaluation. The performance of the HCM Risk-Kids model in predicting risk at 5 years was assessed. Twenty-three patients (5.4%) met the SCD end-point within 5 years, with an overall incidence rate of 2.03 per 100 patient-years [95% confidence interval (CI) 1.48-2.78]. Model validation showed a Harrell's C-index of 0.745 (95% CI 0.52-0.97) and Uno's C-index 0.714 (95% 0.58-0.85) with a calibration slope of 1.15 (95% 0.51-1.80). A 5-year predicted risk threshold of ≥6% identified 17 (73.9%) SCD events with a corresponding C-statistic of 0.702 (95% CI 0.60-0.81).

CONCLUSIONS:

This study reports the first external validation of the HCM Risk-Kids model in a large and geographically diverse patient population. A 5-year predicted risk of ≥6% identified over 70% of events, confirming that HCM Risk-Kids provides a method for individualized risk predictions and shared decision-making in children with HCM.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiomiopatia Hipertrófica / Morte Súbita Cardíaca Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiomiopatia Hipertrófica / Morte Súbita Cardíaca Idioma: En Ano de publicação: 2022 Tipo de documento: Article